Given our finding that high expression of both LSD1 and G9a was correlated with the lowest survival in patients with ESCC, future clinical studies are clearly needed in order to determine whether targeting both LSD1 and G9a can improve PD-1-based therapies. Here, KDM1A is linked to esophageal squamous cell carcinoma.